Science

13018 readers

17 users here now

Studies, research findings, and interesting tidbits from the ever-expanding scientific world.

Subcommunities on Beehaw:

Space

Be sure to also check out these other Fediverse science communities:

This community's icon was made by Aaron Schneider, under the CC-BY-NC-SA 4.0 license.

founded 2 years ago

MODERATORS

Gaywallet@beehaw.org

alyaza@beehaw.org

remington@beehaw.org

Flawed, scandalous trials tank FDA expert support for MDMA therapy (arstechnica.com)

submitted 5 months ago by Powderhorn@beehaw.org to c/science@beehaw.org

7 comments fedilink hide all child comments

Run trials with an astounding number of easily avoidable flaws, win stupid prizes. It would be a shame for this to turn into an overall setback for psychedelic therapy.

Sure, the FDA could go against the recommendation, but that's a political nonstarter given the problems included sexual assault. We need studies that are unassailable on the data collection such that the psychoactive (qualitative) effects are just an outlier in the list of quantitative results.

you are viewing a single comment's thread
view the rest of the comments

[–] autotldr@lemmings.world 3 points 5 months ago

🤖 I'm a bot that provides automatic summaries for articles:

Click here to see the summary

In response to this point, the FDA stunningly admitted in the meeting that it had overlooked the fact that the company didn't plan on collecting that data while it was designing the trial.

Lykos also did not collect enough data on the known cardiovascular effects of MDMA, which could pose significant risks to patients with high blood pressure and heart arrhythmias.

They also claimed that the touch-based psychotherapy technique that Lykos used for the trial ties to dubious cult-like new-age psychospiritual therapy, which, among other things, intends to bring about a "global spiritualized society" and suggests suicidal ideation stems from suffering that occurred in the birth canal.

"Unfortunately, there potentially has been some misconduct ... that has really polluted or corrupted our ability to interpret the data," advisor and psychiatry expert Walter Dunn, of the University of California Los Angeles, said at the end of the meeting.

The FDA does not regulate psychotherapy, and the advisory committee members had several questions about how to standardize a therapy technique that is not yet based on evidence.

Advisor and psychologist Melissa Decker Barone, of the VA Maryland Health Care System, summarized the general feeling of the committee in the discussion period.

Saved 75% of original text.